

Stock Sentiment Analysis Report

Illumina (ILMN)

Analysis Period: 2026-03-07 to 2026-04-06 (30 days)

Generated: 2026-04-06 09:43:10

Executive Summary


Sentiment analysis for Illumina (ILMN) from 2026-03-07 to 2026-04-06. Analyzed 169 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	57	33.7%
Negative	47	27.8%
Neutral	65	38.5%
Total	169	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
Evolution of a truncated nucleocapsid protein enha...	news	2026-04-01	0.869
EBV infection outcomes determined by monocyte and ...	news	2026-03-20	0.840
I'm a wellness writer — 40 of my favorite products...	news	2026-03-25	0.805
Artificial Intelligence in Oncology: Assessment of...	news	2026-03-30	0.799
Plagl1 regulates the retinal progenitor cell to Mü...	news	2026-03-18	0.784

Top Negative Events

Title	Source	Date	Score
Single-cell transcriptome profiling reveals herpes...	news	2026-04-02	-1.000
DNMT1 loss leads to hypermethylation of a subset o...	news	2026-04-02	-0.984
Publisher Correction: Integrated Liquid Biopsy and...	pubmed	2026 Apr 1	-0.872
Biobanking of gynecologic cancer biospecimens: Dev...	news	2026-03-31	-0.869
New phs004508.v1.p1 Dendritic Cell Redundancy ...	news	2026-03-27	-0.869